Business Context and Reporting Period
Nanobiotix S.A. filed this Form 6-K as a foreign private issuer for the month of August 2023. The filing was submitted on August 31, 2023, and references a press release filed as Exhibit 99.1.
The filing identifies Nanobiotix’s principal executive office as 60 Rue de Wattignies, 75012 Paris, France. The company files annual reports on Form 20-F.
Financial Metrics
The filing text provided does not include financial statements or clear values for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
The filing text does not describe material changes versus a prior comparable period. The referenced Exhibit 99.1 press release is not included in the provided content.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, outlook commentary, risk disclosures, contingencies, or unusual items. Any such information may be contained in the referenced press release, which is not provided here.
Investor Verification Items
- Obtain and review Exhibit 99.1, the press release dated August 31, 2023.
- Verify whether the press release contains updated operating results, clinical developments, financing information, guidance, or risk disclosures.
- Confirm the company’s financial position and liquidity using its latest Form 20-F or subsequent periodic filings.